Journal article
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
British journal of haematology, Vol.123(1), pp.110-113
2003
DOI: 10.1046/j.1365-2141.2003.04550.x
PMID: 14510951
Abstract
Calcineurin inhibitor-induced central nervous system toxicities are uncommon and often resolve after discontinuation of the offending drug. The long-term outcome of these patients is, however, unknown. Resolution of symptoms occurred in 70% of 30 allografted recipients who developed calcineurin inhibitor-induced neurotoxicity. When patients were rechallenged with the same or a different calcineurin inhibitor, symptoms recurred in 41%, leading to permanent discontinuation of the drug. De novo or progressive acute graft-versus-host disease (GVHD) was observed in 54% of patients at a median of 7 d (range 1-70 d) after initial onset of neurotoxicity. The prognosis was grim, with 24 (80%) of these patients dying a median 33 d after the onset of neurotoxicity (range 2-594 d). GVHD and/or infection occurred in 54% and were the most common primary causes of death. We conclude that calcineurin inhibitor-induced neurotoxicity is frequently reversible but associated with a poor prognosis.
Details
- Title: Subtitle
- Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
- Creators
- Rizwana CHOHAN - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesRavi VIJ - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesHanna KHOURY - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesDouglas ADKINS - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesWilliam BLUM - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesRandy BROWN - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesMichael TOMASSON - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesSteven DEVINE - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesTimothy GRAUBERT - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesLawrence T GOODNOUGH - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United StatesJohn F DIPERSIO - Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO, United States
- Resource Type
- Journal article
- Publication Details
- British journal of haematology, Vol.123(1), pp.110-113
- DOI
- 10.1046/j.1365-2141.2003.04550.x
- PMID
- 14510951
- NLM abbreviation
- Br J Haematol
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- Publisher
- Blackwell
- Language
- English
- Date published
- 2003
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094499602771
Metrics
27 Record Views